Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
IRCCS Multimedica Hospital, Sesto San Giovanni, Milan, Italy.
Br J Pharmacol. 2017 Nov;174(22):3973-3985. doi: 10.1111/bph.13805. Epub 2017 May 5.
For long time, the role of LDL and inflammation in the pathogenesis of atherosclerosis have been studied independently from each other and only more recently a common platform has been suggested. Accumulation of excess cholesterol due to the presence of increased circulating LDL promotes endothelium dysfunction and activation, which is associated with increased production of pro-inflammatory cytokines, overexpression of adhesion molecules, chemokines and C-reactive protein (CRP), increased generation of reactive oxygen species and reduction of nitric oxide levels and bioavailability. All these processes favour the progressive infiltration of inflammatory cells within the arterial wall where cholesterol accumulates, both extracellularly and intracellularly, and promotes vascular inflammation. According to this, lipid-lowering therapies should improve inflammation and, indeed, statins decrease circulating inflammatory markers such as CRP and improve endothelial function and plaque burden. Pleiotropic activities have been proposed to explain this effect. However, mendelian randomization studies ruled out a direct role for CRP on coronary artery disease and studies with other lipid lowering drugs, such as ezetimibe showed that the beneficial effect of LDL-cholesterol-lowering therapies on systemic inflammatory status, as monitored by changes in CRP plasma levels, could be achieved, independently of the mechanism of action, only in patients presenting with baseline inflamed conditions. These observations strengthen the direct link between cholesterol and inflammation and indicate that decreasing LDL levels is one of the key goals for improving cardiovascular outcome.
This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
长期以来,LDL 和炎症在动脉粥样硬化发病机制中的作用一直是相互独立研究的,直到最近才提出一个共同的平台。由于循环中 LDL 增加导致胆固醇过量积累,促进了内皮功能障碍和激活,这与促炎细胞因子的产生增加、粘附分子、趋化因子和 C 反应蛋白 (CRP) 的过度表达、活性氧的产生增加以及一氧化氮水平和生物利用度的降低有关。所有这些过程都有利于炎症细胞在动脉壁内的渐进浸润,胆固醇在动脉壁内积累,无论是细胞外还是细胞内,并促进血管炎症。根据这一点,降脂治疗应该改善炎症,事实上,他汀类药物可以降低 CRP 等循环炎症标志物,改善内皮功能和斑块负担。提出了多效性活动来解释这种效果。然而,孟德尔随机化研究排除了 CRP 对冠心病的直接作用,而用其他降脂药物(如依折麦布)进行的研究表明,LDL 胆固醇降低治疗对全身炎症状态的有益影响,如 CRP 血浆水平的变化所监测到的,可以实现,独立于作用机制,仅在基线炎症条件下的患者中。这些观察结果加强了胆固醇和炎症之间的直接联系,并表明降低 LDL 水平是改善心血管结局的关键目标之一。
本文是针对炎症靶点以降低心血管疾病风险的专题部分的一部分。要查看本部分中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc 和 http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc。